Nanotechnology for addiction
University of Buffalo (UB) has developed a stable nanoparticle, administered in the dopaminergic neurons, capable of making silent, that is "off" the gene responsible for drug addiction. The press release announcing a homonym universities. The results of the research, carried out by the Institute for Lasers, Photonics and Biophotonics in collaboration with the UB Department of Medicine, was published in yesterday's preview on Proceedings of the National Academy of Sciences (Bonoiu Adela C. et al. Nanotechnology approach for drug addiction therapy: gene silencing using siRNA-delivery of gold nanorods nanoplex in dopaminergic neurons, PNAS, published online before print March 23, 2009).
"This discovery means that in the near future we will be able to develop a new and powerful pharmacological agent effective on a wide range of substance addiction, but the advantage of this new therapeutic approach is that it may one day be useful to those who suffer from Parkinson's, cancer, neurological damage, pichiatrici disorders, dementia and AIDS asthma, for which disorders are already in experimental studies, "said Paras N. Prasad, executive director of UBA Institute for Lasers, Photonics and Biophotonics and coordinator of the research team, as the statement said.
" Nanoparticles have proved a safe and effective way to administer a wide variety of fabrics, new drugs and sophisticated, able to switch off the abnormal genes, "said Stanley A. Schwartz, director of the Division of Allergy, Immunology and Rheumatology of the UB School of Medicine and Biomedical Sciences, co-author of the study.
In practice, the UB researchers have developed a novel technique for silencing of DARPP-32, a protein cevello known to have a role in triggering the cascade of signals involved in addictive drugs do. The DARPP-32 is a brain protein that facilitates the addictive behavior. Making "silent", with a technique called "short interfering RNA (siRNA), the gene encoding DARPP-32E can inhibit the production of this protein in order to prevent drug addiction.
"silence this gene can reduce the physical craving for drugs, "says Adela C. Boniou of UB.
The problem of finding a safe and effective way of administering the siRNA, in itself unstable, has been solved by researchers at UB for the first time a combination of siRNA molecules with nanoparticles cannulate form, called "nanorods".
"It 's the first time you use nanotechnology in therapy, to silence genes in the brain, using techniques RNA stable and secure," said Supriya D. Mahajan of the UB.
They are already on the agenda of researchers at the University of Buffalo in vivo experiments with nanotechnology.